Intellectual Property - May 6, 2019
Nanologica’s patent issued in the US
The United States Patent and Trademark Office has issued the company’s patent titled ”Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients”. The patent protects Nanologica’s technology platform for the delivery of growth factors for stem cell based therapy and provides evidence of successful […]
In a new job - June 14, 2017
New board member at Nanologica
Eva Byröd has been selected as a new member of the Board at Nanologica. “Eva will have an important role in Nanologica’s further development. Her solid experience within the different phases of drug development will be of great value to Nanologica’s efforts in this area,” said Gisela Sitbon, Head of the Board. Eva Byröd has […]
Collaboration - August 26, 2016
Nanologica, GSK collaborate
Nanologica has signed a Services Agreement with GSK to apply its expertise in nanoporous materials and customized drug delivery systems to advance the development of new technology platforms for early stage development projects. ”We are excited about the collaboration with GSK. This is an early, but interesting project with the possibility to unlock new approaches to personalized medicine. […]
Pharma Business - April 23, 2014
Nanologica creates spin-off company
The Swedish high-tech company Nanologica spins off its asset within obesity into a standalone business distributed to the company’s shareholders with Sana Alajmovic serving as CEO. According to an announcement the spin-off is done to speed up development of a new medical product for the treatment of obesity. The new company will go under the name […]
Biotech Award - May 17, 2013
Nanologica nanotech company of the year
Swedish biotech company Nanologica has been awarded with the title Nanotech Company of the year. Nanologica received the award during SwedNanoTech’s Nano Forum in Stockholm. The event was held on Wednesday May 15. The jury’s motivation for selecting Nanologica to receive the award reads: “A company with roots in Swedish university research, with a clear mission and […]
New Market - February 27, 2013
Nanologica enters Russian market
The Stockholm-based biotech company Nanologica AB recently announced a new collaboration with the Russian biotech company Nanolek LLC. The contract concerns a formulation of pharmaceutical drug products using Nanologica’s patented nanoporous materials platform and the manufacture of new drugs, whereby Nanologica is responsible for formulating active pharmaceutical ingredients into porous particles. Nanolek will develop, manufacture […]
